Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Annual vaccines are recommended for the seasonal influenza virus. While yearly updates to the vaccine are necessary due to the constant evolution of influenza viruses, some studies have suggested repeat vaccination may result in a reduction in vaccine effectiveness in subsequent years. This review examines the available evidence that repeated annual influenza virus vaccination may have effects on future vaccine responses, and it synthesizes the available data with studies that may indicate potential immunological mechanisms underlying these effects. The goal is to examine the available literature to determine whether these mechanisms can be subverted to improve seasonal influenza virus vaccine efficacy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12020744 | PMC |
| http://dx.doi.org/10.1084/jem.20241283 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New Indazole Derivatives as Potential Scaffolds for the Development of Anticancer, Antiviral, and Anti-tuberculosis Chemotherapeutic Compounds.
Curr Med Chem
September 2025
Laboratory of Molecular Basis of Action of physiologically active compounds, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, Russia.
Introduction: Chemotherapy remains essential despite advances in immunotherapy, radiotherapy, and biological therapy. However, the wide range of chemical drugs is limited by a narrow therapeutic index, low selectivity, and the development of resistance. In this regard, new high-efficiency drugs are in extremely high demand.
View Article and Find Full Text PDFH5N1 influenza virus-like particles based on BEVS induce robust functional antibodies and immune responses.
Virology
August 2025
Changchun Institute of Biological Products Co.,Ltd, Changchun, China; State Key Laboratory of Novel Vaccines for Emerging Infectious Diseases, China National Biotec Group Company Limited, Beijing, China. Electronic address:
Avian influenza virus infections pose a potential pandemic threat. The currently licensed vaccines have inherent limitations, emphasizing the urgent need for improved influenza vaccines. Here, we developed a novel hemagglutinin (HA) virus-like particle (VLP) vaccine candidate through the baculovirus expression vector system (BEVS).
View Article and Find Full Text PDFCost-Effectiveness Analysis of a Maternal Vaccination Program Against Respiratory Syncytial Virus in Norway.
Influenza Other Respir Viruses
September 2025
Oslo Economics, Oslo, Norway.
Background: Respiratory syncytial virus (RSV) is recognized as the primary cause of hospitalizations among children with lower respiratory tract infections in developed countries, placing a significant burden on both patients and healthcare systems. The efficacy, safety, and immunogenicity of maternal vaccination with the novel RSVpreF vaccine have been evaluated in a Phase III clinical trial, showing a decreased risk of severe infection in infants. Our study assesses the cost-effectiveness of the RSVpreF vaccine and seasonal variation of costs in a Norwegian setting.
View Article and Find Full Text PDFMapping the infectious burden in VEXAS syndrome: a systematic review and rationale for prevention.
Lancet Rheumatol
September 2025
Service de Médecine interne et polyvalente, Centre Hospitalier du Haut-Anjou, Château-Gontier, France; Université d'Angers, Inserm, CNRS, MITOVASC, Equipe MitoLab, SFR ICAT, F-49000 Angers, France. Electronic address:
Infections are increasingly recognised as a major cause of morbidity and mortality in patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. We conducted a systematic review to characterise the infectious burden of VEXAS syndrome and propose preventive strategies. We included 57 studies (813 patients) showing that infections in patients with VEXAS syndrome were frequent, severe in 40-60% of cases, and fatal in 6-15% of cases.
View Article and Find Full Text PDFInterferon-γ receptor signaling is critical for balanced immune activation and protection against influenza after vaccination.
Virology
September 2025
Center for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA. Electronic address:
To better understand the contribution of interferon-γ (IFN-γ) receptor signaling to vaccine-induced immunity, we employed A129 (IFN-α/β receptor-deficient) and AG129 (IFN-α/β/γ receptor-deficient) mouse models. AG129 mice induced comparable levels of virus-specific IgG after vaccination with influenza virus H5 hemagglutinin (HA) virus-like particles (VLPs). Vaccinated AG129 mice with HA VLPs exhibited impaired Th1-immune responses, lower hemagglutination inhibition (HAI) titers, increased susceptibility to virus infection, and lower survival rates following influenza virus (H5N1) challenge than vaccinated A129 mice.
View Article and Find Full Text PDF